Intellia Therapeutics, Inc. (NTLA) Financials

NTLA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 857.2 million 129.5 million
March 31, 2026 758.8 million 137.8 million
Dec. 31, 2025 842.1 million 170.7 million
Sept. 30, 2025 925.3 million 176.9 million

NTLA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -202.3 million 31.6 million
March 31, 2026 -117.4 million 13.5 million
Dec. 31, 2025 -69.4 million 90.8 million
Sept. 30, 2025 -76.9 million 19.6 million

NTLA Net Income

No data available :(

NTLA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 437.8 million - 73.4 million
March 31, 2026 376.0 million 61.4 million 19.1 million
Dec. 31, 2025 449.9 million 66.8 million 26.5 million
Sept. 30, 2025 511.0 million - 98.0 million

NTLA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 133.5 million
March 31, 2026 118.5 million
Dec. 31, 2025 108.4 million
Sept. 30, 2025 110.2 million

NTLA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1.9 million 82.6 million 37.8 million -
March 31, 2026 79000 80.7 million 34.8 million -
Dec. 31, 2025 126000 88.7 million 33.1 million -
Sept. 30, 2025 29000 94.7 million 46.3 million 15.8 million

NTLA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 7.7 million -
March 31, 2026 15.0 million 2.2 million
Dec. 31, 2025 23.0 million 6.0 million
Sept. 30, 2025 13.8 million 78.9 million

NTLA

Price: $11.56

52 week price:
7.95
28.25

Earnings Per Share: -3.37 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Ebitda: -15.1 million

Market Capitalization: 1.7 billion

Links: